Company intelligence / Profile preview
Scholar Rock
Cambridge, Massachusetts, United Statesscholarrock.com ↗
- Ownership
- Public · SRRK
- Employees
- ~150
- Development stage
- Other
01
Overview
Scholar Rock’s lead asset, apitegromab—a selective anti-latent myostatin antibody—is in Phase 3 for spinal muscular atrophy with a BLA submission and commercial launch anticipated in late 2025. The company also has programs in obesity (Phase 2), cardiometabolic disorders (preclinical), and iron-restricted anemia (preclinical). Their approach enables highly selective inhibition of disease-driving growth factors before activation, potentially overcoming limitations of traditional therapies[1][3].
- Therapeutic areas
- HematologyEndocrinologyCardiovascularNeurology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Exploring partnerships to maximize their technology’s potential; no major pharma partners publicly disclosed as of May 2025[3].
04
Financials
- Market cap
- $5.5B
- Total revenue
- $0
- Enterprise value
- $5.3B
Beyond the preview
Go deeper on Scholar Rock.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scholar Rock.